14 Toxicokinetics (TK) CROs

What is Toxicokinetics (TK) and when do you need it?

Toxicokinetics is the exposure arm of a toxicology study. Where the tox study tells you what happened to the animal at a given dose, TK tells you how much drug was actually in the blood when it happened. Without that link, a No-Observed-Adverse-Effect-Level (NOAEL) is just a milligram-per-kilogram number that means little across species. TK turns it into an exposure value, usually Cmax and AUC, that a reviewer can scale to a human starting dose and a safety margin. That is the whole reason the work exists.

You need TK during the IND-enabling stage, embedded inside the pivotal GLP toxicology studies rather than run as a standalone effort. The standard design follows ICH S3A: serial or composite blood sampling from the tox animals on day 1 and again at steady state late in the study, often from satellite animals in the rodent arm so the main-study animals are not bled to the point of confounding the toxicity readout. The non-rodent species (dog, minipig, or non-human primate) is usually sampled directly. TK confirms three things a reviewer looks for: that exposure went up with dose, that it accumulated (or did not) on repeat dosing, and how the margin at the NOAEL compares to your intended clinical exposure.

A point that trips up first-time sponsors: TK is not the same as DMPK or the dedicated PK work you did in preclinical. Those are separate, earlier studies in healthy animals at lower, non-toxic doses, designed to characterize absorption and metabolism. TK lives at the high, toxic doses inside the safety study itself, and its job is narrower: prove the animals got the systemic exposure the study claims, and express the safety findings in units that translate to people. The two share a bioanalytical backbone, which is why the same lab often runs both, but the regulatory purpose is different.

What does a Toxicokinetics (TK) CRO actually do?

A TK CRO does two connected jobs. First, it designs and runs the exposure sampling that rides along with the GLP tox study: setting the sampling schedule, deciding satellite versus main-study animals, collecting plasma at the right timepoints around dosing, and handling the samples so the drug does not degrade before analysis. Second, and this is the part that actually gates your timeline, it runs the validated bioanalytical method that quantifies your compound and any relevant metabolites in those samples, then computes the TK parameters (Cmax, Tmax, AUC, accumulation ratio) and writes the section that feeds the tox report.

The bioanalysis is where most of the risk sits. For a small molecule that means a validated LC-MS/MS method; for a biologic it means a ligand-binding assay (ELISA or an MSD electrochemiluminescence platform), and for some programs an ADA assay running alongside to flag whether anti-drug antibodies are eroding exposure over the dosing period. Method validation has to meet the bar in ICH M10, the harmonized bioanalytical method validation guideline, because a reviewer will check that the exposure numbers underpinning your safety story came from a method validated to the right standard. A TK package built on a fit-for-purpose-only method, when the submission needed a fully validated one, is a study you may have to repeat. Most TK CROs sit inside a larger GLP toxicology operation, so when you source a tox study the TK and bioanalysis typically come as part of the same scope rather than a separate vendor.

How to choose a Toxicokinetics (TK) CRO?

The single most important question is whether the bioanalytical method and the GLP tox program live under one roof or get split across two vendors. A split adds a sample-shipping handoff, a second contract, and a coordination seam right on the critical path, because the tox report cannot finalize until the TK data lands. If you can source TK and tox together, do it. When you compare TK CROs on BioBridgeX, score them against the same written scope and weight regulatory track record over headline price. A repeated exposure study costs far more than the saving on a cheaper quote.

• Quality and GxP status: confirm the bioanalytical method will be validated to ICH M10 and the study runs under GLP (21 CFR Part 58 or OECD GLP), and ask for recent FDA or relevant-agency inspection history.
• Capacity and lead time: TK rides the tox study timeline, so confirm the GLP slot, the bioanalytical queue, and the report turnaround. Method development plus validation is often the hidden rate-limiter, not the in-life phase.
• Modality and indication fit: small-molecule LC-MS/MS is a different skill set from a biologic ligand-binding assay or an ADA panel for a cell or gene therapy. Match the assay platform to your molecule before anything else.
• Region and regulatory track record: ask how many programs the team has supported through an actual FDA, EMA, or PMDA review, and make sure the method validation standard matches where you intend to file.
• Data quality: ask to see how they handle the lower limit of quantification a low-dose program needs, incurred sample reanalysis (ISR), and how exposure margins and accumulation are reported and reconciled against the tox findings.
• IP and confidentiality: confirm sample chain-of-custody, who owns the method and the raw data, and how analytical records transfer to you for the submission.